Head-to-head · Cost-Efficiency Index
Ivy Rx vs WeightRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Ivy Rx
Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms.
Visit Ivy RxWeightRx
Cost-first shoppers who want the lowest published tirzepatide figure, if you are willing to complete intake before you can read the plan terms.
Visit WeightRxThe verdict
Ivy Rx and WeightRx tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with Ivy Rx (ranked #102, a hair above #109) — Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms. But WeightRx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Ivy Rx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Ivy Rx | WeightRx |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $97/mo (microdose tier, promotional rate, compounded) | $250/mo (compounded) |
| Tirzepatide / mo | $199/mo (brand Mounjaro, compounded) | $83/mo (term not published, compounded) |
| Semaglutide / yr (modeled) | $1,164 | $3,000 |
| Tirzepatide / yr (modeled) | $2,388 | $996 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #102 | #109 |
Ivy Rx
69/100Where the value is
- Genuinely low entry price on the semaglutide microdose tier ($77/mo)
- HSA/FSA eligible with itemized receipts for reimbursement
- Legal entity is named (Ivy RX PLLC), which many competitors in this batch do not disclose
The tradeoffs
- The standard semaglutide price is shown as a struck-through discount ('$197 $97') with no label clarifying whether $97 is a standing rate or a temporary promo
- The advertised $199/mo tirzepatide rate requires a 12-month upfront lump-sum payment, not month-to-month billing, and a separate unexplained $1,399 vial price appears on the same page
WeightRx
69/100Where the value is
- The tirzepatide figure is published up front, and it is genuinely low against the field
- Both molecules are offered
- No membership charge is advertised alongside the medication rate
The tradeoffs
- The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
- Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.